Profile data is unavailable for this security.
About the company
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.
- Revenue in USD (TTM)132.06m
- Net income in USD-198.76m
- Incorporated2016
- Employees296.00
- LocationArcutis Biotherapeutics Inc3027 Townsgate Road, Suite 300WESTLAKE VILLAGE 91361United StatesUSA
- Phone+1 (805) 418-5006
- Fax+1 (302) 636-5454
- Websitehttps://arcutis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharvaris NV | 0.00 | -126.85m | 1.09bn | 82.00 | -- | 2.96 | -- | -- | -2.66 | -2.66 | 0.00 | 6.85 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Travere Therapeutics Inc | 177.64m | -383.45m | 1.10bn | 380.00 | -- | 72.43 | -- | 6.18 | -4.99 | -1.88 | 2.31 | 0.1981 | 0.2759 | 0.7613 | 7.92 | 467,484.20 | -59.56 | -36.95 | -74.41 | -44.77 | 94.70 | 95.92 | -215.85 | -165.79 | 2.99 | -- | 0.9615 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| AnaptysBio Inc | 30.47m | -170.12m | 1.10bn | 117.00 | -- | 101.55 | -- | 36.22 | -6.34 | -6.34 | 1.14 | 0.3601 | 0.0645 | -- | 5.00 | 260,453.00 | -36.02 | -18.08 | -39.45 | -18.96 | -- | -- | -558.25 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| CARGO Therapeutics Inc | 0.00 | -147.71m | 1.11bn | 116.00 | -- | 2.54 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -64.74m | 1.14bn | 50.00 | -- | 3.87 | -- | -- | -2.16 | -2.16 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Phathom Pharmaceuticals Inc | 9.92m | -297.11m | 1.15bn | 452.00 | -- | -- | -- | 115.55 | -5.13 | -5.13 | 0.1717 | -3.99 | 0.0339 | 1.72 | -- | 21,942.48 | -101.68 | -83.26 | -115.19 | -93.77 | 80.15 | -- | -2,995.68 | -135,982.00 | 6.44 | -5.74 | 1.86 | -- | -- | -- | -1.96 | -- | -- | -- |
| Cogent Biosciences Inc | 0.00 | -227.05m | 1.15bn | 164.00 | -- | 4.45 | -- | -- | -2.48 | -2.48 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -55.22 | -49.53 | -60.02 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| Prothena Corporation PLC | 217.25m | -50.92m | 1.16bn | 173.00 | -- | 1.98 | -- | 5.32 | -1.01 | -1.01 | 3.94 | 10.82 | 0.318 | -- | 829.18 | 1,255,757.00 | -7.45 | -14.20 | -8.16 | -15.11 | -- | -- | -23.44 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Day One Biopharmaceuticals Inc | 8.19m | -167.48m | 1.21bn | 169.00 | -- | 3.94 | -- | 147.73 | -1.94 | -1.94 | 0.0948 | 3.50 | 0.0193 | -- | -- | 52,851.61 | -39.35 | -- | -45.70 | -- | 91.37 | -- | -2,044.43 | -- | 4.09 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
| Arcutis Biotherapeutics Inc | 132.06m | -198.76m | 1.22bn | 296.00 | -- | 6.50 | -- | 9.21 | -2.18 | -2.18 | 1.36 | 1.60 | 0.3451 | 0.8334 | 4.36 | 446,155.40 | -51.93 | -65.64 | -58.68 | -71.72 | 92.32 | -- | -150.51 | -1,513.03 | 8.19 | -5.94 | 0.5223 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| Tyra Biosciences Inc | 0.00 | -80.88m | 1.23bn | 49.00 | -- | 3.25 | -- | -- | -1.69 | -1.69 | 0.00 | 7.13 | 0.00 | -- | -- | 0.00 | -25.18 | -- | -25.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
| Relay Therapeutics Inc | 35.21m | -322.83m | 1.23bn | 304.00 | -- | 1.48 | -- | 34.85 | -2.52 | -2.52 | 0.277 | 5.11 | 0.0406 | -- | -- | 109,003.10 | -37.22 | -28.55 | -39.91 | -29.54 | -- | -- | -916.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
| Gyre Therapeutics Inc | 165.85m | -79.66m | 1.30bn | 593.00 | -- | 19.66 | -- | 7.81 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| ARS Pharmaceuticals Inc | 500.00k | -44.84m | 1.36bn | 23.00 | -- | 6.33 | -- | 2,724.06 | -0.466 | -0.466 | 0.0052 | 2.22 | 0.0021 | -- | -- | 20,833.33 | -18.66 | -20.37 | -19.33 | -21.32 | -- | -- | -8,968.40 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Data as of Sep 19 2024. Currency figures normalised to Arcutis Biotherapeutics Inc's reporting currency: US Dollar USD
58.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Jennison Associates LLCas of 30 Jun 2024 | 11.57m | 9.90% |
| Suvretta Capital Management LLCas of 30 Jun 2024 | 10.00m | 8.56% |
| Rubric Capital Management LPas of 30 Jun 2024 | 9.82m | 8.40% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 7.66m | 6.55% |
| Polar Capital LLPas of 30 Jun 2024 | 6.88m | 5.89% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 5.86m | 5.01% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 5.13m | 4.39% |
| Franklin Advisers, Inc.as of 30 Jun 2024 | 4.44m | 3.80% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 3.62m | 3.10% |
| Gilder, Gagnon, Howe & Co. LLCas of 30 Jun 2024 | 3.62m | 3.09% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
